Literature DB >> 21922597

Fine-tiling array CGH to improve diagnostics for α- and β-thalassemia rearrangements.

Marion Phylipsen1, Attawut Chaibunruang, Ingrid P Vogelaar, Jeetindra R A Balak, Rianne A C Schaap, Yavuz Ariyurek, Supan Fucharoen, Johan T den Dunnen, Piero C Giordano, Egbert Bakker, Cornelis L Harteveld.   

Abstract

Implementation of multiplex ligation-dependent probe amplification (MLPA) for thalassemia causing deletions has lead to the detection of new rearrangements. Knowledge of the exact breakpoint sequences should give more insight into the molecular mechanisms underlying these rearrangements, and would facilitate the design of gap-PCRs. We have designed a custom fine-tiling array with oligonucleotides covering the complete globin gene clusters. We hybridized 27 DNA samples containing newly identified deletions and nine positive controls. We designed specific primers to amplify relatively short fragments containing the breakpoint sequence and analyzed these by direct sequencing. Results from nine positive controls showed that array comparative genomic hybridization (aCGH) is suitable to detect small and large rearrangements. We were able to locate all breakpoints to a region of approximately 2 kb. We designed breakpoint primers for 22 cases and amplification was successful in 19 cases. For 12 of these, the exact locations of the breakpoints were determined. Seven of these deletions have not been reported before. aCGH is a valuable tool for high-resolution breakpoint characterization. The combination of MLPA and aCGH has lead to relatively cheap and easy to perform PCR assays, which might be of use for laboratories as an alternative for MLPA in populations where only a limited number of specific deletions occur with high frequency.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21922597     DOI: 10.1002/humu.21612

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

1.  Characterization of Deletions of the HBA and HBB Loci by Array Comparative Genomic Hybridization.

Authors:  Daniel E Sabath; Michael A Bender; Vijay G Sankaran; Esther Vamos; Alex Kentsis; Hye-Son Yi; Harvey A Greisman
Journal:  J Mol Diagn       Date:  2015-11-21       Impact factor: 5.568

Review 2.  Disease-targeted sequencing: a cornerstone in the clinic.

Authors:  Heidi L Rehm
Journal:  Nat Rev Genet       Date:  2013-03-12       Impact factor: 53.242

Review 3.  From Prenatal to Preimplantation Genetic Diagnosis of β-Thalassemia. Prevention Model in 8748 Cases: 40 Years of Single Center Experience.

Authors:  Giovanni Monni; Cristina Peddes; Ambra Iuculano; Rosa Maria Ibba
Journal:  J Clin Med       Date:  2018-02-20       Impact factor: 4.241

4.  ATR-16 syndrome: mechanisms linking monosomy to phenotype.

Authors:  Christian Babbs; Jill Brown; Sharon W Horsley; Joanne Slater; Evie Maifoshie; Shiwangini Kumar; Paul Ooijevaar; Marjolein Kriek; Amanda Dixon-McIver; Cornelis L Harteveld; Jan Traeger-Synodinos; Andrew O M Wilkie; Douglas R Higgs; Veronica J Buckle
Journal:  J Med Genet       Date:  2020-01-31       Impact factor: 6.318

5.  Detection of four rare thalassemia variants using Single-molecule realtime sequencing.

Authors:  Shiqiang Luo; Xingyuan Chen; Dingyuan Zeng; Ning Tang; Dejian Yuan; Bailing Liu; Lizhu Chen; Qingyan Zhong; Jiaqi Li; Yinyin Liu; Jianping Chen; Xiaoyuan Wang; Tizhen Yan
Journal:  Front Genet       Date:  2022-09-02       Impact factor: 4.772

6.  Diagnosis of Sickle Cell Disease and HBB Haplotyping in the Era of Personalized Medicine: Role of Next Generation Sequencing.

Authors:  Adekunle Adekile; Nagihan Akbulut-Jeradi; Rasha Al Khaldi; Maria Jinky Fernandez; Jalaja Sukumaran
Journal:  J Pers Med       Date:  2021-05-23

7.  Breakpoint characterization of a rare alpha0 -thalassemia deletion using targeted locus amplification on genomic DNA.

Authors:  Quint P Hottentot; Emile de Meijer; Henk P J Buermans; Stefan J White; Cornelis L Harteveld
Journal:  Int J Lab Hematol       Date:  2021-07-12       Impact factor: 3.450

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.